BioNTech is a German biotechnology company founded in 2008, specializing in the development of immunotherapies for cancer and infectious diseases. The name “BioNTech” reflects its focus on biotechnology (“Bio”) and its emphasis on innovative technologies (“Tech”) aimed at harnessing the body’s immune system for therapeutic purposes. It gained global prominence for its collaboration with Pfizer to develop one of the first mRNA vaccines for COVID-19, which demonstrated the potential of mRNA technology in rapid vaccine development. BioNTech also works on treatments leveraging personalized medicine and aims to address various diseases through advanced biotechnological approaches.
BioNTech is transitioning from COVID-19 vaccine success to focus on mRNA-based cancer therapies. Despite a decline in revenue and profits, BioNTech's financial performance in 2024 exceeded market expectations, with earnings…